- Home
- REFR vs BCAB Comparison
REFR vs BCAB Comparison
Compare REFR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- BCAB
- Stock Information
- Founded
- REFR 1965
- BCAB 2007
- Country
- REFR United States
- BCAB United States
- Employees
- REFR N/A
- BCAB N/A
- Industry
- REFR Multi-Sector Companies
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- REFR Miscellaneous
- BCAB Health Care
- Exchange
- REFR Nasdaq
- BCAB Nasdaq
- Market Cap
- REFR N/A
- BCAB 22.3M
- IPO Year
- REFR N/A
- BCAB 2020
- Fundamental
- Price
- REFR $1.64
- BCAB $0.38
- Analyst Decision
- REFR
- BCAB Buy
- Analyst Count
- REFR 0
- BCAB 2
- Target Price
- REFR N/A
- BCAB $1.00
- AVG Volume (30 Days)
- REFR 27.1K
- BCAB 507.7K
- Earning Date
- REFR 07-31-2025
- BCAB 08-07-2025
- Dividend Yield
- REFR N/A
- BCAB N/A
- EPS Growth
- REFR N/A
- BCAB N/A
- EPS
- REFR N/A
- BCAB N/A
- Revenue
- REFR $1,581,929.00
- BCAB $11,000,000.00
- Revenue This Year
- REFR N/A
- BCAB N/A
- Revenue Next Year
- REFR N/A
- BCAB N/A
- P/E Ratio
- REFR N/A
- BCAB N/A
- Revenue Growth
- REFR 62.28
- BCAB N/A
- 52 Week Low
- REFR $0.93
- BCAB $0.24
- 52 Week High
- REFR $2.39
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- REFR 45.20
- BCAB 42.24
- Support Level
- REFR $1.54
- BCAB $0.36
- Resistance Level
- REFR $1.84
- BCAB $0.43
- Average True Range (ATR)
- REFR 0.13
- BCAB 0.04
- MACD
- REFR -0.04
- BCAB -0.00
- Stochastic Oscillator
- REFR 25.00
- BCAB 16.00
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.